Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study)
نویسندگان
چکیده
BACKGROUND/OBJECTIVES Severe Crohn's disease impacts negatively on individual quality of life, with treatment options limited once conventional therapies have been exhausted. The aim of this study was to explore factors influencing decision-making and expectations of people considering or participating in the Autologous Haematopoietic Stem Cell Treatment trial. METHODS An international, cross-sectional qualitative study, involving semistructured face to face interviews across five sites (four UK and one Spain). 38 participants were interviewed (13 men, 25 women; age range 23-67 years; mean age 37 years). The mean age at diagnosis was 20 years. Interviews were audio recorded and transcribed verbatim and transcripts were analysed using a framework approach. RESULTS Four themes emerged from the analysis: (1) 'making your mind up'-a determination to receive stem cell treatment despite potential risks; (2) communicating and understanding risks and benefits; (3) non-participation-your choice or mine? (4) recovery and reframing of personal expectations. CONCLUSIONS Decision-making and expectations of people with severe Crohn's disease in relation to autologous haematopoietic stem cell treatment is a complex process influenced by participants' histories of battling with their condition, a frequent willingness to consider novel treatment options despite potential risks and, in some cases, a raised level of expectation about the benefits of trial participation. Discussions with patients who are considering novel treatments should take into account potential 'therapeutic misestimation', thereby enhancing shared decision-making, informed consent and the communication with those deemed non-eligible. ASTIC TRIAL EUDRACT NUMBER 2005-003337-40: results.
منابع مشابه
Relation between Age, Gender, Number of Blood Products Received and Diagnosis with Engraftment and Length of Hospital Stay in Patients Undergoing Autologous Stem Cell Transplantation
Background and purpose: Autologous hematopoietic stem cell transplantation may be one of the best treatment options for some patients with hematological malignancies. The process of stem cell homing in the bone marrow and the production and proliferation of denovo cell populations is called engraftment and could be considered as one of the key factors in the success of stem cell transplantation...
متن کاملP 53: Stem Cell Therapy for Treatment of Autoimmune Diseases (with Emphasis on Multiple Sclerosis)
Autoimmune diseases have been described as an interesting and poorly understood group of disorders. There are many challenges in the respective scientific societies concerning the nature, causes and the therapeutic approaches of these diseases. In accordance with the evidences the nature and etiology of these disorders is multifactorial and complex but the clearest definition could be expressed...
متن کاملDoes Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study
Background: Mesenchymal stem cells (MSCs) with their potential to differentiate into mesodermal and non-mesodermal lineages have several immunomodulatory characteris-tics. These properties make them promising tools in cell and gene therapy. Objective: To evaluate the potential therapeutic applications of autologous MSC in improving clinical manifestations of MS patients. Methods: Ten patients w...
متن کاملEvaluation of Therapeutic Effects of Autologous Bone Marrow Mesenchymal Stem Cells to Prevent the Progression of Chronic Nephropathy in Renal Transplant
Background Chronic allograft nephropathy(CAN) is one of the most common causes of chronic and end stage renal disease. It is defined with Mainly tubular atrophy and interstitial fibrosis and no evidence of any other etiology, or functional disorder that caused at least three months after transplantation . Control of risk factors (HTN,DM,HLP, …) and limiting usage of calcineurin inhibitors...
متن کاملP96: Progress in the Treatment of Alzheimer’s Disease by Gene Therapy
Alzheimer’s disease (AD) is a progressive neurological disorder characterized by the aggregation of two proteins, amyloid-b and hyper phosphorylated tau, and by neuronal and synaptic loss. The progress of gene-modified cells and stem cells is a particularly promising therapeutic method for AD. Gene-Modified Cell-Based Therapy for AD prior to transplantation can be beneficial for increasin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 7 شماره
صفحات -
تاریخ انتشار 2017